S219: FIRST CLINICAL STUDY OF THE ANTI-SIGNAL REGULATORY PROTEIN-ALPHA (SIRPΑ) ANTIBODY CC-95251 COMBINED WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)

• P. Strati,
• E. Hawkes,
• N. Ghosh,
• J. Tuscano,
• Q. Chu,
• M. A. Anderson,
• A. Patel,
• M. R. Burgess,
• K. Hege,
• S. Chhagan,
• S. Boyanapalli,
• T. Day,
• F. Shen,
• A. Mehta

Affiliations

P. Strati

1 The University of Texas MD Anderson Cancer Center, Houston, United States of America

E. Hawkes

2 Austin Health–Austin Hospital, Heidelberg, Australia

N. Ghosh

3 Levine Cancer Institute, Charlotte

J. Tuscano

4 University of California, Davis, Sacramento, United States of America

Q. Chu

5 Cross Cancer Institute, Edmonton, Canada

M. A. Anderson

6 Peter MacCallum Cancer Centre, Melbourne, Australia

A. Patel

7 Bristol Myers Squibb, Princeton

M. R. Burgess

7 Bristol Myers Squibb, Princeton

K. Hege

7 Bristol Myers Squibb, Princeton

S. Chhagan

7 Bristol Myers Squibb, Princeton

S. Boyanapalli

7 Bristol Myers Squibb, Princeton

T. Day

7 Bristol Myers Squibb, Princeton

F. Shen

7 Bristol Myers Squibb, Princeton

A. Mehta

8 University of Alabama at Birmingham, Birmingham, United States of America